Compare CAL & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAL | VOGX |
|---|---|---|
| Founded | 1878 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.1M | 456.5M |
| IPO Year | 1994 | 2026 |
| Metric | CAL | VOGX |
|---|---|---|
| Price | $12.21 | $33.75 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 460.8K | 248.8K |
| Earning Date | 05-28-2026 | N/A |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $85,513,000.00 | N/A |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $2.45 | N/A |
| P/E Ratio | $27.95 | ★ N/A |
| Revenue Growth | ★ 0.46 | N/A |
| 52 Week Low | $8.80 | $14.80 |
| 52 Week High | $16.14 | $35.50 |
| Indicator | CAL | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 95.54 |
| Support Level | $11.24 | $27.37 |
| Resistance Level | $11.92 | $34.61 |
| Average True Range (ATR) | 0.52 | 4.45 |
| MACD | -0.23 | 0.98 |
| Stochastic Oscillator | 5.65 | 90.43 |
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - Famous Footwear and Brand Portfolio. The Famous Footwear segment is comprised of its Famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. This segment is comprised of wholesale operations that designs, develops, sources, manufactures, markets and distributes branded, licensed and private-label footwear. Geographically, the company generates the majority of its revenue from Domestic operations.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.